Stockscreener 앱 받기
15.40
0.79%
0.12
전일 마감가:
$15.28
열려 있는:
$15.4
하루 거래량:
381.33K
Relative Volume:
0.59
시가총액:
$929.39M
수익:
$1.23M
순이익/손실:
$-214.90M
주가수익비율:
-3.7359
EPS:
-4.1222
순현금흐름:
$-151.25M
1주 성능:
+2.60%
1개월 성능:
+1.92%
6개월 성능:
-44.30%
1년 성능:
-55.94%
1일 변동 폭
$14.92
$15.68
1주일 범위
$14.75
$15.71
52주 변동 폭
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
SYRE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
15.40 | 904.70M | 1.23M | -214.90M | -151.25M | -4.1222 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
Spyre Therapeutics to Participate in Upcoming June Investor Conferences - Eastern Progress
Wall Street Analysts Predict a 244.05% Upside in Spyre Therapeutics (SYRE): Here's What You Should Know - sharewise
Millennium Management LLC Acquires Shares of 167,804 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics to Participate in Upcoming June Investor Conf - GuruFocus
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of “Buy” by Analysts - Defense World
Spyre Therapeutics IBD Pipeline Updates Coming at Major June Healthcare Conferences - Stock Titan
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Deutsche Bank AG - Defense World
BNP Paribas Financial Markets Takes $437,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
How Much Upside is Left in Spyre Therapeutics (SYRE)? Wall Street Analysts Think 258.34% - Yahoo Finance
First Trust Advisors LP Invests $548,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 12.6% on Earnings Beat - Defense World
Spyre Therapeutics: Q1 Earnings Snapshot - New Haven Register
Spyre Therapeutics Reports Q1 2025 Financial Results - TipRanks
Spyre (SYRE) Advances Clinical Trials with Strong Financial Backing | SYRE Stock News - GuruFocus
Spyre Therapeutics Inc Reports Q1 2025 EPS of -$0.60, Beating Estimates, Amid $44.8 Million Net Loss - GuruFocus
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Position Boosted by Tower Research Capital LLC TRC - The AM Reporter
MetLife Investment Management LLC Has $498,000 Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - The AM Reporter
Spyre Therapeutics (NASDAQ:SYRE) Given Outperform Rating at Wedbush - Defense World
Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $49.57 - Defense World
Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025 - Nasdaq
Spyre Therapeutics (SYRE) Showcases Promising IBD Treatment Data at Upcoming Conference | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 | SYRE Stock News - GuruFocus
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001 - PR Newswire
Invesco Ltd. Sells 118,195 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Wells Fargo & Company MN Purchases 6,908 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Announces Grants of Inducement Awards | SYRE Stock News - GuruFocus
Spyre Therapeutics Awards 64,400 Shares in Stock Options to Strategic New Employee Hires - Stock Titan
Spyre Therapeutics (SYRE) to Release Earnings on Thursday - Defense World
Barclays PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Analyzing Ratios: Arcutis Biotherapeutics Inc (ARQT)’s Financial Story Unveiled - DWinneX
JPMorgan Chase & Co. Purchases 5,775 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics Inc [SYRE] stock for 246,313 USD was sold by Albers Jeffrey W. - knoxdaily.com
Are Smart Investors Making the Right Decision? Spyre Therapeutics Inc (SYRE) - Sete News
Have you been able to find a good deal on Spyre Therapeutics Inc’s shares? - uspostnews.com
Analyzing the Impact of Earnings Reports on Spyre Therapeutics Inc Inc. (SYRE) Price Performance - investchronicle.com
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Purchased by Geode Capital Management LLC - The AM Reporter
What is Leerink Partnrs’ Forecast for SYRE Q1 Earnings? - The AM Reporter
Vanguard Group Inc. Buys 330,553 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Q1 Earnings Estimate for SYRE Issued By Leerink Partnrs - Defense World
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $50.33 Consensus Price Target from Brokerages - Defense World
Corebridge Financial Inc. Has $401,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Leerink Partnrs Upgrades Spyre Therapeutics (NASDAQ:SYRE) to “Strong-Buy” - Defense World
KLP Kapitalforvaltning AS Invests $182,000 in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Leerink Partners - Defense World
Leerink Partners Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform Recommendation - Nasdaq
Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target - marketscreener.com
Biotech Spyre Therapeutics Awards 93,200 Stock Options in Key Talent Push - Stock Titan
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.48%
자본화:
|
볼륨(24시간):